Navigation Links
Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results
Date:11/9/2009

BEIJING, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc. (Nasdaq: YONG), ("Yongye or "the Company") a leading manufacturer, developer and distributor of Shengmingsu brand plant and animal nutrient products in the People's Republic of China (PRC), today announced that it will conduct a conference call at 10:00 a.m. Eastern Time (11:00 p.m. Beijing Time) on Monday, November 16, 2009 to discuss results for the quarter ended September 30, 2009.

To participate in this live conference call, please dial (888) 419-5570 five to ten minutes prior to the scheduled conference call time. International callers should dial (617) 896-9871. The conference pass code is 120 619 18.

For those individuals who are unable to participate in the conference call, a replay will be available for fourteen days starting on November 16, at 12:00 p.m. Eastern Time. To access the replay, please dial (888) 286-8010. International callers should dial (617) 801-6888. The replay pass code is 402 454 82.

Interested parties may also listen to the live conference call via webcast and access the replay by visiting http://www.yongyeintl.com/webcast.html .

About Yongye International, Inc.

Yongye International, Inc., headquartered in Beijing, is engaged in the manufacturing, development, distribution and sales of Shengmingsu brand plant and animal nutrient products. The Company's patented and patent pending formulas and proprietary extraction processes allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Inner Mongolia Yongye Nongfeng Biotechnology Co., Ltd., is headquartered in Beijing with administrative and sales offices located in Inner Mongolia, People's Republic of China. For more information, please visit the Company's website at http://www.yongyeintl.com .

Safe Harbor Statement

This press release contains certain statements that may include "forward- looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

     Yongye International, Inc.
     Mr. Larry Gilmore-VP of Corporate Strategy
     Phone: +86-10-8232-8866 x8880
     Email: larry.gilmore@yongyeintl.com

     CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE Yongye International, Inc.


'/>"/>
SOURCE Yongye International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye International Announces 2010-2012 Strategic Plan
2. Yongye International Announces Expansion of Research and Development Center
3. Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores
4. Yongye Biotechnology International Receives License to Manufacture Products
5. Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance
6. Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day
7. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
8. Yongye Biotechnology Appoints New Chief Financial Officer
9. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
10. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
11. Yongye Biotechnology International to Expand its Network of Branded Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... VA (PRWEB) , ... December 07, 2016 , ... ... medical journal has concluded that “in the setting of previously treated, advanced pancreatic ... refinement in defining the optimal patient population and timing of blood sampling may ...
(Date:12/7/2016)... Mich. , Dec. 7, 2016 Neogen ... has named Dr. Dan Kephart as its ... company. Kephart will assume his responsibilities at Neogen effective ... and development director for the agribusiness unit of Thermo ... safety development at Life Technologies. His extensive industry experience ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... SAN DIEGO , Dec. 7, 2016  Biocom, the ... community, issued the statement below following passage of 21 st ... the House on November 30 by a 392-26 vote and ... This statement may be attributed to Joe Panetta , ... historic legislation that will give hope to millions of patients ...
Breaking Biology Technology:
(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
Breaking Biology News(10 mins):